BioTuesdays

Category - Markets

Intellia Therapeutics
Markets

Leerink upgrades Intellia Therapeutics to outperform

Leerink Partners upgraded Intellia Therapeutics (NASDAQ:NTLA) to “outperform” from “market perform” on valuation, with a price target of $32. The stock closed at $17.66 on Thursday. “We believe the current valuation...

August 5, 2016
Pieris Pharmaceuticals
Markets

Roth reinitiates coverage of Pieris Pharma at buy

Roth Capital Partners reinitiated coverage of Pieris Pharmaceuticals (NASDAQ:PIRS) with a “buy” rating and $6 price target. The stock closed at $1.70 on Thursday. “We believe the company’s anticalin platform has broad...

August 5, 2016
Radius Health Logo
Markets

Maxim downgrades Radius Health to sell

Maxim Group downgraded Radius Health (NASDAQ:RDUS) to “sell” from “hold” with a $24 price target. The stock closed at $50.55 on Thursday. “At the current valuation, we believe that Radius is back to an overvalued...

August 4, 2016
William Blair
Markets

WB downgrades EndoChoice to market perform

William Blair downgraded EndoChoice Holdings (NYSE:GI) to “market perform,” citing lower-than-expected second quarter results and reduced guidance. The stock closed at $5.26 on Wednesday. “While we continue to view...

August 4, 2016
TearLab
Markets

Roth downgrades TearLab to neutral

Roth Capital Partners downgraded TearLab (NASDAQ:TEAR; TSX:TLB) to “neutral” from “buy,” citing sales transition challenges. The stock closed at 83 cents on Wednesday. Analyst Chris Lewis writes that TearLab’s second...

August 4, 2016
Galmed Logo
Markets

HCW cuts Galmed Pharma price target to $13

H.C. Wainwright lowered its price target to Galmed Pharmaceuticals (NASDAQ:GLMD) to $13 from $22, citing enrollment delays in a Phase 2b NASH trial of aramchol. The stock closed at $4.13 on Wednesday. “Given that Galmed...

August 4, 2016
Synthetic Biologics Logo
Markets

WB cuts Synthetic Biologics price target

William Blair lowered its price target for Synthetic Biologics (NYSE:SYN) to $7 from $10, citing potential delays to commercialize the company’s two programs. The stock closed at $1.67 on Wednesday. “We maintain our...

August 4, 2016
Derma Sciences
Markets

Roth ups Derma Sciences price target to $8.50

Roth Capital Markets raised its price target for Derma Sciences (NASDAQ:DSCI) to $8.50 from $7.25. The stock was quoted at $5.04 in afternoon trading on Wednesday. Analyst Scott Henry writes that his updated model...

August 3, 2016
Keryx Biopharmaceuticals Logo
Markets

Stifel downgrades Keryx to hold

Stifel downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “hold” from “buy” and removed its price target after the company announced an imminent supply disruption with its Auryxia product. The stock closed at $4.72 on...

August 2, 2016